var data={"title":"Antithymocyte globulin (rabbit derived, Thymoglobulin): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Antithymocyte globulin (rabbit derived, Thymoglobulin): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5654?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information\" class=\"drug drug_general\">see &quot;Antithymocyte globulin (rabbit derived, Thymoglobulin): Drug information&quot;</a> and <a href=\"topic.htm?path=antithymocyte-globulin-rabbit-derived-thymoglobulin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Antithymocyte globulin (rabbit derived, Thymoglobulin): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708632\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Experienced physician:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Anti-thymocyte globulin should only be used by physicians experienced in immunosuppressive therapy in transplantation.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135993\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Thymoglobulin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20858411\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Thymoglobulin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045257\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Immunosuppressant Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045249\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information\" class=\"drug drug_general\">see &quot;Antithymocyte globulin (rabbit derived, Thymoglobulin): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:<b> Note:</b> Premedicate with corticosteroids, acetaminophen, and/or an antihistamine 1 hour prior to infusion to reduce the incidence and severity of infusion-related reactions. Administer antifungal and antibacterial prophylaxis therapy if clinically indicated. For use in solid organ transplantation (ie, kidney), antiviral prophylaxis is recommended in patients who are CMV-seropositive at the time of transplant and for CMV-seronegative patients scheduled to receive a kidney from a CMV-seropositive donor.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Aplastic anemia; refractory: </b>Limited data available: Children and Adolescents: IV: 3.5 mg/kg/day once daily for 5 days in combination with cyclosporine (Di Bona 1999; Scheinberg 2006; Takahashi 2013); <b>Note:</b> Consistent with observations in adult patients, rabbit-antithymocyte globulin is less effective than horse-antithymocyte globulin when either combined with cyclosporine in children and adolescents for initial treatment of severe aplastic anemia (Marsh 2009; Scheinberg 2011; Yoshimi 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hematopoietic stem cell transplant; graft-versus-host disease (GVHD) prevention: </b>Limited data available; regimens and protocols variable; refer to institutional protocols: Infants, Children, and Adolescents: IV: Usual reported TOTAL dose range: 4.5 to 15 mg/kg total divided into 3 to 5 once daily doses administered pretransplant; usual regimen is 3 to 4 doses on consecutive days in combination with chemotherapy or radiation (Admiraal 2015; Aversa 2005; Horn 2006; Kang 2016; Locatelli 2017; Soni 2014; Willemsen 2015). In adolescents &ge;16 years, a lower total dose and timing approach has been successfully used: IV: 0.5 mg/kg/day 2 days before transplantation, 2 mg/kg/day 1 day before transplantation, and 2 mg/kg/day 1 day after transplantation (total dose: 4.5 mg/kg; in addition to standard GVHD prophylaxis) (Walker 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Solid organ transplantation: Note: </b>Doses and timing may vary; refer to institutional specific protocols:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i> Kidney transplantation: </i>Infant, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Induction, prophylaxis: IV: 1.5 mg/kg/dose once daily for 4 to 10 doses initiated at time of transplant prior to reperfusion of donor kidney; during variable and dependent on other immunosuppressive regimens (Khositseth 2005; Li 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Acute rejection, treatment: IV: 1.5 mg/kg/dose once daily for 7 to 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Heart/lung transplantation: </i>Limited data available: Infant, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Induction, prophylaxis: Reported range: IV: 1 to 2 mg/kg/dose once daily infused over 12 hours for 5 days; dose dependent on baseline platelet count; in trials the following doses were used based on platelet count (Di Filippo 2003):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;150,000/mm<sup>3</sup>: IV: 2 mg/kg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">100,000 to 150,000/mm<sup>3</sup>: IV: 1.5 mg/kg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">50,000 to &lt;100,000/mm<sup>3</sup>: IV: 1 mg/kg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Acute rejection, treatment: IV: 2 mg/kg/dose once daily for 5 days (Di Filippo 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Liver, intestinal, or multivisceral transplant</i>: Limited data available: Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Induction, prophylaxis: IV: Total dose of 5 mg/kg divided into separate pre- and post-op doses: 2 to 3 mg/kg over 6 to 8 hours before allograft reperfusion, followed by the remainder 2 to 3 mg/kg over 6 to 8 hours post-operative; used in combination with other immunosuppressives (Bond 2005; Reyes 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Rejection: 1.5 mg/kg/dose once daily; duration variable (usually at least 4 to 5 days) based upon biopsy results (Schmitt 2010; Thangarajah 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: Acute renal transplant rejection: 1.5 mg/kg/day once daily for 7 to 14 days</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135985\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Thymoglobulin: 25 mg (1 ea) [contains glycine, mannitol, sodium chloride]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135975\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045260\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral: Administer by slow IV infusion over 6 to 12 hours for the preconditioning/induction dose or over 6 hours for the initial acute rejection treatment dose; infuse over 4 hours for subsequent doses if first dose tolerated. Administer through an in-line filter with pore size of 0.22 microns via central line or high flow vein. Premedication  with corticosteroids, acetaminophen, and/or an antihistamine may reduce infusion-related reactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F639179\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store intact vial at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze. Protect from light. Reconstituted product is stable for up to 24 hours at room temperature; however, the product contains no preservative and room temperature storage is not recommended; the manufacturer recommends use immediately after reconstitution and preparation for infusion in D5W or NS.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045259\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Prophylaxis for and treatment of acute rejection of renal transplant; used in conjunction with concomitant immunosuppression (FDA approved in pediatric patients [age not specified] and adults); has also been used for treatment of aplastic anemia; prevention and/or treatment of acute rejection after bone marrow, heart/lung, liver, intestinal, or multivisceral transplantation in conjunction with other immunosuppressive agents</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9885364\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Antithymocyte globulin rabbit (Thymoglobulin) may be confused with antithymocyte globulin equine (Atgam)</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136009\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Chest pain, edema, hypertension, hypotension, peripheral edema, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Anxiety, chills, headache, insomnia, malaise, pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Acne vulgaris, diaphoresis, pruritus, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Acidosis, hyperkalemia, hypokalemia, hypophosphatemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, anorexia, constipation, diarrhea, dyspepsia, gastritis, intestinal candidiasis, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia, leukocytosis, leukopenia, malignant neoplasm, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Serum sickness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Cytomegalovirus disease, herpes simplex infection, infection, sepsis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, back pain, myalgia, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Dyspnea, increased cough, pulmonary disease</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Drug overdose, fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Anaphylaxis, blood coagulation disorder, cytokine release syndrome, decreased oxygen saturation, increased liver enzymes, infusion-related reaction, lymphadenopathy, lymphoproliferative disorder (posttransplant), malignant lymphoma, proteinuria, solid tumor</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135990\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity (allergy or anaphylaxis) to rabbit proteins or any component of the formulation; active acute or chronic infection which contraindicate additional immunosuppression</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for drugs in this class is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135979\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic effects: Reversible leukopenia, neutropenia, thrombocytopenia, and lymphopenia may occur. Monitor blood counts. Leukopenia and/or thrombocytopenia may require dosage adjustment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity and fatal anaphylactic reactions have been reported. Stop infusion immediately if anaphylactic reaction occurs. Immediate treatment (including subcutaneous epinephrine and corticosteroids) should be available during infusion for management of hypersensitivity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infection: Severe infections (bacterial, fungal, viral and/or protozoal) may develop following concomitant use of immunosuppressants with antithymocyte globulin. Reactivation of infections (particularly CMV) and sepsis have been reported. Appropriate antiviral, antibacterial, antiprotozoal, and/or antifungal prophylaxis is recommended. Monitor closely for infection.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infusion reactions: Release of cytokines by activated monocytes and lymphocytes may lead to cytokine release syndrome (CRS) during infusion; may cause serious cardiopulmonary events (sometimes fatal). Rapid infusion rates have been associated with CRS (case reports). Other infusion reaction symptoms, including flu-like symptoms (fever, chills, nausea, muscle/joint pain) may also occur. Local infusion site reactions (pain, swelling, skin redness) have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Malignancy: Immunosuppressants, including antithymocyte globulins may increase the incidence of malignancies, including lymphoma, post-transplant lymphoproliferative disease (PTLD) or other malignancies; may be fatal.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunizations: Patients should not be immunized with attenuated live viral vaccines during or shortly after treatment; safety of immunization following therapy has not been studied.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Disease-related concerns:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Liver transplantation induction: Antithymocyte globulin (rabbit) has been associated with increased adverse effects when used for induction in liver transplantation and should be used cautiously in this population (Boillot 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Administration: Initial dose must be administered over at least 6 hours into a high flow vein. Reducing the infusion rate (and prolonging the administration time) may minimize infusion reactions. May pretreat with an antipyretic, antihistamine, and/or corticosteroid.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Experienced physician: <b>[US Boxed Warning]: Should only be used by physicians experienced in immunosuppressive therapy in transplantation.</b> Maintenance immunosuppression may require dosage reduction. Medical surveillance is required during the infusion. Should be administered in combination with other immunosuppressants.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Product selection: Antithymocyte globulin (ATG) (rabbit) is available (based on region) in different product formulations, ATG-Thymoglobulin and ATG-Fresenius; the dosing differs among the formulations. Dosing of antithymocyte globulin (rabbit) also differs from dosing of other antithymocyte globulin products (eg, ATG [equine]); protein compositions and concentrations are different. Use caution to ensure dose prescribed is intended for product being administered.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298764\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6218046\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13168&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Belatacept: Antithymocyte Globulin (Rabbit) may enhance the adverse/toxic effect of Belatacept. Specifically, the risk for venous thrombosis of the renal allograft may be increased.  Management: A 12-hour interval between administration of these 2 agents is suggested if these agents are to be used concomitantly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F639176\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Animal reproduction studies have not been conducted. Females of reproductive potential should use effective contraception during and for at least 3 months following treatment.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The National Transplantation Pregnancy Registry (NTPR) is a registry which follows pregnancies which occur in maternal transplant recipients or those fathered by male transplant recipients. The NTPR encourages reporting of pregnancies following solid organ transplant by contacting them at 877-955-6877 or NTPR@giftoflifeinstitute.org.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045256\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Platelet count, CBC with differential, lymphocyte count, vital signs during infusion</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135978\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Antithymocyte globulin (rabbit) is a polyclonal antibody which appears to cause immunosuppression by acting on T-cell surface antigens and depleting CD4 lymphocytes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135989\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action (T-cell depletion): Within 24 hours (Hardinger 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Lymphopenia may persist for up to 1 year (Hardinger 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 2 to 3 days</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322995\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Thymoglobulin Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (1): $957.96</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038531\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>ATG-Fresenius (CY);</li>\n      <li>ATG-Fresinius (EE, SE);</li>\n      <li>Thymoglobulin (DE);</li>\n      <li>Thymoglobuline (AT, AU, BG, BR, CH, CN, CZ, DK, FI, FR, GB, GR, HK, IE, IT, KR, LU, LV, MT, MY, NL, NO, PL, SG, SI, TH, ZA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Admiraal R, van Kesteren C, Jol-van der Zijde CM, et al. Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis. <i>Lancet Haematol</i>. 2015;2(5):e194-203.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-pediatric-drug-information/abstract-text/26688094/pubmed\" target=\"_blank\" id=\"26688094\">26688094</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aversa F, Terenzi A, Tabilio A, et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. <i>J Clin Oncol</i>. 2005;23(15):3447-3454.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-pediatric-drug-information/abstract-text/15753458/pubmed\" target=\"_blank\" id=\"15753458\">15753458</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19877264\"></a>Boillot O, Seket B, Dumortier J, et al. Thymoglobulin induction in liver transplant recipients with a tacrolimus, mycophenolate mofetil, and steroid immunosuppressive regimen: a five-year randomized prospective study. <i>Liver Transpl</i>. 2009;15(11):1426-1434.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-pediatric-drug-information/abstract-text/19877264/pubmed\" target=\"_blank\" id=\"19877264\">19877264</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bond GJ, Mazariegos GV, Sindhi R, Abu-Elmagd KM, Reyes J. Evolutionary experience with immunosuppression in pediatric intestinal transplantation. <i>J Pediatr Surg</i>. 2005;40(1):274-279; discussion 279-280.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-pediatric-drug-information/abstract-text/15868597/pubmed\" target=\"_blank\" id=\"15868597\">15868597</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Di Bona E, Rodeghiero F, Bruno B, et al. Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy. Gruppo Italiano Trapianto di Midollo Osseo (GITMO). <i>Br J Haematol</i>. 1999;107(2):330-334.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-pediatric-drug-information/abstract-text/10583220/pubmed\" target=\"_blank\" id=\"10583220\">10583220</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Di Filippo S, Boissonnat P, Sassolas F, et al, &ldquo;Rabbit Antithymocyte Globulin as Induction Immunotherapy in Pediatric Heart Transplantation,&rdquo; <i>Transplantation</i>, 2003, 75(3):354-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-pediatric-drug-information/abstract-text/12589158 /pubmed\" target=\"_blank\" id=\"12589158 \">12589158 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Garcia Aroz S, Tzvetanov I, Hetterman EA, et al. Long-term outcomes of living-related small intestinal transplantation in children: A single-center experience. <i>Pediatr Transplant</i>. 2017;21(4).<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-pediatric-drug-information/abstract-text/28295952/pubmed\" target=\"_blank\" id=\"28295952\">28295952</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17125438\"></a>Hardinger KL. Rabbit antithymocyte globulin induction therapy in adult renal transplantation. <i>Pharmacotherapy</i>. 2006;26(12):1771-1783.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-pediatric-drug-information/abstract-text/17125438/pubmed\" target=\"_blank\" id=\"17125438\">17125438</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hertig A, Zuckermann A. Rabbit antithymocyte globulin induction and risk of post-transplant lymphoproliferative disease in adult and pediatric solid organ transplantation: An update. <i>Transpl Immunol</i>. 2015;32(3):179-187.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-pediatric-drug-information/abstract-text/25936966/pubmed\" target=\"_blank\" id=\"25936966\">25936966</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Horan JT, Liesveld JL, Fenton P, et al, &ldquo;Hematopoietic Stem Cell Transplantation for Multiply Transfused Patients With Sickle Cell Disease and Thalassemia After Low-Dose Total Body Irradiation, Fludarabine, and Rabbit Anti-thymocyte Globulin,&rdquo; <i>Bone Marrow Transplant</i>, 2005, 35(2):171-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-pediatric-drug-information/abstract-text/15531901/pubmed\" target=\"_blank\" id=\"15531901\">15531901</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Horn B, Baxter-Lowe LA, Englert L, et al. Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML. <i>Bone Marrow Transplant</i>. 2006;37(3):263-269.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-pediatric-drug-information/abstract-text/16327813/pubmed\" target=\"_blank\" id=\"16327813\">16327813</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kang HJ, Hong KT, Lee JW, et al. Improved Outcome of a Reduced Toxicity-Fludarabine, Cyclophosphamide, plus Antithymocyte Globulin Conditioning Regimen for Unrelated Donor Transplantation in Severe Aplastic Anemia: Comparison of 2 Multicenter Prospective Studies. <i>Biol Blood Marrow Transplant</i>. 2016;22(8):1455-1459.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-pediatric-drug-information/abstract-text/27090956/pubmed\" target=\"_blank\" id=\"27090956\">27090956</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Khositseth S, Matas A, Cook ME, Gillingham KJ, Chavers BM. Thymoglobulin versus ATGAM induction therapy in pediatric kidney transplant recipients: a single-center report. <i>Transplantation</i>. 2005;79(8):958-963.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-pediatric-drug-information/abstract-text/15849550/pubmed\" target=\"_blank\" id=\"15849550\">15849550</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Li L, Chaudhuri A, Chen A, et al. Efficacy and safety of thymoglobulin induction as an alternative approach for steroid-free maintenance immunosuppression in pediatric renal transplantation. <i>Transplantation</i>. 2010;90(12):1516-1520.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-pediatric-drug-information/abstract-text/20935596/pubmed\" target=\"_blank\" id=\"20935596\">20935596</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Locatelli F, Bernardo ME, Bertaina A, et al. Efficacy of two different doses of rabbit anti-T-lymphocyte globulin to prevent graft-versus-host disease in children with haematological malignancies transplanted from an unrelated donor: a multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncol</i>. 2017;18(8):1126-1136.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-pediatric-drug-information/abstract-text/28705454/pubmed\" target=\"_blank\" id=\"28705454\">28705454</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marsh JC, Ball SE, Cavenagh J, et al. Guidelines for the diagnosis and management of aplastic anaemia. <i>Br J Haematol</i>. 2009;147(1):43-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-pediatric-drug-information/abstract-text/19673883/pubmed\" target=\"_blank\" id=\"19673883\">19673883</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15888051\"></a>Reyes J, Mazariegos GV, Abu-Elmagd K, et al. Intestinal transplantation under tacrolimus monotherapy after perioperative lymphoid depletion with rabbit anti-thymocyte globulin (thymoglobulin). <i>Am J Transplant</i>. 2005;5(6):1430-1436.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-pediatric-drug-information/abstract-text/15888051/pubmed\" target=\"_blank\" id=\"15888051\">15888051</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Scheinberg P, Nunez O, Weinstein B, et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. <i>N Engl J Med</i>. 2011;365(5):430-438.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-pediatric-drug-information/abstract-text/21812672/pubmed\" target=\"_blank\" id=\"21812672\">21812672</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Scheinberg P, Nunez O, Young NS. Retreatment with rabbit anti-thymocyte globulin and ciclosporin for patients with relapsed or refractory severe aplastic anaemia. <i>Br J Haematol</i>. 2006;133(6):622-627.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-pediatric-drug-information/abstract-text/16704436/pubmed\" target=\"_blank\" id=\"16704436\">16704436</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schmitt TM, Phillips M, Sawyer RG, et al. Anti-thymocyte globulin for the treatment of acute cellular rejection following liver transplantation. <i>Dig Dis Sci</i>. 2010;55(11):3224-3234.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-pediatric-drug-information/abstract-text/20238251/pubmed\" target=\"_blank\" id=\"20238251\">20238251</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Soni S, Gross TG, Rangarajan H, Baker KS, Sturm M, Rhodes M. Outcomes of matched sibling donor hematopoietic stem cell transplantation for severe sickle cell disease with myeloablative conditioning and intermediate-dose of rabbit anti-thymocyte globulin. <i>Pediatr Blood Cancer</i>. 2014;61(9):1685-1689.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-pediatric-drug-information/abstract-text/24740582/pubmed\" target=\"_blank\" id=\"24740582\">24740582</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Starzl TE, Murase N, Abu-Elmagd K, et al, &ldquo;Tolerogenic Immunosuppression for Organ Transplantation,&rdquo; <i>Lancet</i>, 2003, 361(9368):1502-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-pediatric-drug-information/abstract-text/12737859/pubmed\" target=\"_blank\" id=\"12737859\">12737859</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Takahashi Y, Muramatsu H, Sakata N, et al. Rabbit antithymocyte globulin and cyclosporine as first-line therapy for children with acquired aplastic anemia. <i>Blood</i>. 2013;121(5):862-863.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-pediatric-drug-information/abstract-text/23372154/pubmed\" target=\"_blank\" id=\"23372154\">23372154</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thangarajah D, O'Meara M, Dhawan A. Management of acute rejection in paediatric liver transplantation. <i>Paediatr Drugs</i>. 2013;15(6):459-471.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-pediatric-drug-information/abstract-text/23925711/pubmed\" target=\"_blank\" id=\"23925711\">23925711</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thymoglobulin [package insert], Cambridge, MA: Genzyme Corp; April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trissel LA and Saenz CA, &ldquo;Physical Compatibility of Antithymocyte Globulin (Rabbit) With Heparin Sodium and Hydrocortisone Sodium Succinate,&rdquo; <i>Am J Health Syst Pharm</i>, 2003, 60(16):1650-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-pediatric-drug-information/abstract-text/12966908/pubmed\" target=\"_blank\" id=\"12966908\">12966908</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26723083\"></a>Walker I, Panzarella T, Couban S, et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial. <i>Lancet Oncol</i>. 2016;17(2):164-173.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-pediatric-drug-information/abstract-text/26723083/pubmed\" target=\"_blank\" id=\"26723083\">26723083</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Willemsen L, Jol-van der Zijde CM, Admiraal R, et al. Impact of serotherapy on immune reconstitution and survival outcomes after stem cell transplantations in children: thymoglobulin versus alemtuzumab. <i>Biol Blood Marrow Transplant</i>. 2015;21(3):473-482.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-pediatric-drug-information/abstract-text/25485863/pubmed\" target=\"_blank\" id=\"25485863\">25485863</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yoshimi A, Niemeyer CM, F&uuml;hrer MM, Strahm B. Comparison of the efficacy of rabbit and horse antithymocyte globulin for the treatment of severe aplastic anemia in children. <i>Blood</i>. 2013;121(5):860-861.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-pediatric-drug-information/abstract-text/23372153/pubmed\" target=\"_blank\" id=\"23372153\">23372153</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13168 Version 103.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708632\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F135993\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F20858411\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1045257\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1045249\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F135985\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F135975\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1045260\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F639179\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1045259\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F9885364\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F136009\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F135990\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F135979\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298764\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6218046\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F639176\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1045256\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F135978\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F135989\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322995\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038531\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13168|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information\" class=\"drug drug_general\">Antithymocyte globulin (rabbit derived, Thymoglobulin): Drug information</a></li><li><a href=\"topic.htm?path=antithymocyte-globulin-rabbit-derived-thymoglobulin-patient-drug-information\" class=\"drug drug_patient\">Antithymocyte globulin (rabbit derived, Thymoglobulin): Patient drug information</a></li></ul></div></div>","javascript":null}